Advances in incretin-based drug discovery in 2025

The efficacy of anti-obesity drugs that use glucagon-like peptide 1 receptor agonism and glucose-dependent insulinotropic polypeptide agonism raises critical questions about how next-generation drugs might offer increased metabolic benefits. In 2025, new research into incretin-based treatments has b...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Endocrinology 2026-02, Vol.22 (2), p.68-69
Main Author: Müller, Timo D.
Format: Article
Language:English
Subjects:
Agonists
Blood pressure
Body weight loss
Cholesterol
Diabetes
Diabetes mellitus (non-insulin dependent)
Drug dosages
GIP protein
GLP-1 receptor agonists
Glucagon
Glucagon-like peptide 1
Nausea
Obesity
Patients
Peptides
Side effects
Weight control
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!